The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|April 20, 2020
Catalent Releases a Corporate Responsibility Report for Fiscal 2019
Author(s)Pharmaceutical Technology Editors
The report outlines the company’s approaches to product quality, safety, environmental sustainability, and diversity and inclusion.
Advertisement
On April 14, 2020, Catalent published its first
According to a company press release, the report outlines the company’s approaches to product quality, safety, environmental sustainability, and diversity and inclusion. Specific points mentioned include Catalent’s global accreditation under ISO 14001 and the Occupational Health and Safety Assessment Series 18001, the establishment of a goal to reduce its carbon emissions by 15 percent by 2023 by investing in energy efficiency and renewable energy, the company’s introduction of additional volunteer programs, and its commitment to fostering a more inclusive workplace by signing a CEO Action for Diversity and Inclusion pledge.
“Responsible business practices reflect our deep commitment to our mission and values,” said John Chiminski, Catalent’s chair and CEO, in the press release. “This report communicates our CR priorities and progress at an enterprise level, demonstrating Catalent’s ongoing commitment to long-term value-creation and sustainability by investing in people, the environment, and our communities.”
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement